Patent intelligence · EP
EP 3752616
ZUSAMMENSETZUNGEN UND VERFAHREN ZUR GENEDITIERUNG DURCH TARGETING VON FIBRINOGEN-ALPHA
ZUSAMMENSETZUNGEN UND VERFAHREN ZUR GENEDITIERUNG DURCH TARGETING VON FIBRINOGEN-ALPHA
Patent details — EP 3752616
- Jurisdiction
- EP
- Status
- granted
- Grant date
- Dec 23, 2020
- Expiration
- Dec 18, 2040
- Applicant
- CRISPR THERAPEUTICS AG [CH]
- CPC classes
- A61K 48/ 00 A I, A61K/480008, A61K/48005
Quick answer
EP 3752616 (ZUSAMMENSETZUNGEN UND VERFAHREN ZUR GENEDITIERUNG DURCH TARGETING VON FIBRINOGEN-ALPHA) is held by CRISPR THERAPEUTICS AG [CH]. Status: granted. Granted Dec 23, 2020. Expires Dec 18, 2040 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CRISPR THERAPEUTICS AG [CH]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 48/ 00 A I, A61K/480008, A61K/48005
More from CRISPR THERAPEUTICS AG [CH]
Related pharmaceutical patents in our USPTO index.
-
WO 2024052517
USAGE MÉDICAL D'ANTICORPS ANTI-CCR8 ET PROGRAMME DE DOSAGE
granted -
CN 117186084
Pranlerivir sulfonate, and pharmaceutical preparation, preparation method and application thereof in treatment of herpes virus
granted -
CN 115348859
Ophthalmic formulations comprising n-[5-(aminosulfonyl)-4-methyl-1, 3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl) phenyl] acetamide hemihydrate
granted -
CN 115003329
Parapoxvirus for conditioning and treating coronavirus infections
granted -
BR 112021015776
Edição de gene para hemofilia a com expressão de fator viii melhorada
granted -
WO 2021152186
ANTICORPS CCR8 POUR APPLICATIONS THÉRAPEUTIQUES
granted -
DE 102019218587
Kontrastmittelbasierte Gefäßdarstellung
granted -
DE 102019218589
Simultane Bilddarstellung von zwei unterschiedlichen funktionellen Bereichen
granted
Frequently asked questions
What is US patent 3752616?
EP 3752616 (ZUSAMMENSETZUNGEN UND VERFAHREN ZUR GENEDITIERUNG DURCH TARGETING VON FIBRINOGEN-ALPHA) is held by CRISPR THERAPEUTICS AG [CH]. Status: granted. Granted Dec 23, 2020. Expires Dec 18, 2040 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns EP 3752616?
CRISPR THERAPEUTICS AG [CH] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 24 pharmaceutical patents for this assignee.
When does EP 3752616 expire?
Our index shows an expiration date of Dec 18, 2040 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.